SOON Sonova Holding AG
Sonova Holding AG manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through Hearing Instruments, Cochlear Implants, and Lifestyle-Aligned segments. The Hearing Instruments segment engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing instruments and related products under the Advanced Bionics brand. The Lifestyle-Aligned segment designs connected solutions and integrating AI and digital capabilities. It sells its products directly to end consumers through its own store network; wholesales to independent audiologists, third party retail chains, and multinational and government customers; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.…
Industry Peers
Medical DevicesKey Statistics
About Sonova Holding (SWX: SOON)
›
Sonova Holding (SWX: SOON) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 18,837 employees.
The shares were at 293.40 CHF on 19 November 2026, up 34.4% over 52 weeks. Its 52-week range is 163.00 CHF to 296.20 CHF, and it trades at the top of that range.
At a market capitalisation of 17.47B CHF, it trades at 29.1 times trailing earnings and 23.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, a premium of 15% for SOON. It pays a dividend yielding 1.62% (it pays out 47% of its earnings), against a median of 2.41% among the dividend payers in that peer group.
Sonova Holding reports return on equity of 16.5%, an operating margin of 20.6% and revenue up 6.7% year over year.
Its debt exceeds its cash by 1.08B CHF, a debt-to-equity ratio of 0.65. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 19 analysts cover the stock, with an average rating of Hold; their mean price target of 278.32 CHF is 5.1% below the current price. The next earnings report is expected on 21 May 2027.